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Mutant KRAS promotes malignant pleural
effusion formation
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Malignant pleural effusion (MPE) is the lethal consequence of various human cancers
metastatic to the pleural cavity. However, the mechanisms responsible for the development of
MPE are still obscure. Here we show that mutant KRAS is important for MPE induction in
mice. Pleural disseminated, mutant KRAS bearing tumour cells upregulate and systemically
release chemokine ligand 2 (CCL2) into the bloodstream to mobilize myeloid cells from the
host bone marrow to the pleural space via the spleen. These cells promote MPE formation,
as indicated by splenectomy and splenocyte restoration experiments. In addition, KRAS
mutations are frequently detected in human MPE and cell lines isolated thereof, but are often
lost during automated analyses, as indicated by manual versus automated examination of
Sanger sequencing traces. Finally, the novel KRAS inhibitor deltarasin and a monoclonal
antibody directed against CCL2 are equally effective against an experimental mouse model
of MPE, a result that holds promise for future efﬁcient therapies against the human condition.
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T
he pleural cavities of two million cancer patients per year
are affected by malignant pleural effusion (MPE), caused
by primary malignant pleural mesothelioma or by meta-
static cancers originating from the lung, breast, gastrointestinal
tract or elsewhere1. MPE manifests with vascular leakiness
that leads to ﬂuid accumulation in the pleural space and is
etiologically associated with fulminant inﬂammation and
neovascularization, rather than mere tumour-induced lymphatic
obstruction2. However, the reason why some patients with pleural
tumours develop MPE while others do not remains unknown3.
This dichotomous phenotype of ‘wet’ pleural carcinomatosis
associated with a MPE versus ‘dry’ pleural carcinomatosis without
a MPE is critical, since patients with even minimal effusions face
a worse prognosis and limited treatment options3,4. Our previous
work on experimental mouse models of MPE revealed that
pleural tumour-secreted C–C motif chemokine ligand 2 (CCL2)
mediates MPE formation by stimulating angiogenesis and
vascular leakage and by driving myeloid cells, including
monocytes and mast cells, from the bone marrow to the pleural
metastatic milieu5–7. However, the molecular culprits responsible
for tumour cell CCL2 secretion and subsequent MPE
precipitation remain unknown.
EGFR, KRAS, PIK3CA, BRAF, MET, EML4/ALK, RET and
other mutations have been identiﬁed in pleural tumour biopsies
and pleural ﬂuid aspirates from MPE patients8–16. EGFR
mutations were recently implicated in MPE development and
patients with KRAS-mutant lung adenocarcinomas were found
to have more frequent pleural metastases compared with
wild-type ones17–19. However, no study has addressed the role
of KRAS mutations in MPE development.
We hypothesized that the ability of a tumour cell to induce a
MPE once it homes to the pleural space is linked with an
underlying molecular signature. To test this and to model the
biologic events that follow pleural metastasis, we determined the
mutation status of multiple murine and human cancer cell lines
and simultaneously tested their ability to induce MPE by directly
injecting them into the pleural space of appropriate recipient
mice. Our results indicate that pleural homed cancer cells
harboring activating KRAS mutations are competent of
MPE induction. Moreover, we provide evidence that this
genotype-phenotype link is primarily mediated via mutant
KRAS-dependent CCL2 signalling that results in the recruitment
of CD11bþGr1þ myeloid cells to the pleural space, a
phenomenon requiring intact splenic function. Importantly, we
show that KRAS mutations are detectable in human MPE by
careful analyses of Sanger sequencing traces and that mutant
KRAS-mediated MPE is actionable.
Results
A link between KRAS mutations and MPE. To identify a pos-
sible MPE-associated genotype, we cross-examined ﬁve murine
C57BL/6-derived and ﬁve human cancer cell lines for genotype
and MPE competence. For this, we directly injected 1.5 105
mouse or 106 human tumour cells or 3 106 HEK293T benign
human embryonic kidney cells into the pleural cavities of C57BL/6
(mouse cells) or NOD/SCID (human cells) mice. In parallel, we
Sanqer-sequenced the Kras, Egfr, Pik3ca and Braf transcripts of
mouse cells after reverse-transcribing them to cDNAs and
amplifying them with speciﬁc primers (Supplementary Table 1),
and obtained mutation data for KRAS, EGFR, PIK3CA and
BRAF genes of human cells from COSMIC20. KRAS mutations of
human cells were also veriﬁed in-house. Among mouse cells,
three Kras-mutant (Lewis lung carcinoma, LLC; MC38 colon
adenocarcinoma; and AE17 malignant pleural mesothelioma,
bearing heterozygous KrasG12C, KrasG13R, and KrasG12C
mutations, respectively) and two Kras wild-type (B16F10 skin
melanoma and PANO2 pancreatic adenocarcinoma) cell lines
were identiﬁed, which were all free of additional mutations in
Egfr, Pik3ca or Braf genes (Fig. 1a; Table 1). Among human cells,
A549 lung adenocarcinoma cells and their derivatives, long-term
passaged (LTP) A549 cells that have suffered Y chromosome loss,
featured a heterozygous KRASG12S mutation, while SKMEL2 skin
melanoma, HT-29 colon adenocarcinoma, and HEK293T human
embryonic kidney cells were KRAS wild-type (Table 1). These
human cell lines also had wild-type EGFR, PIK3CA and BRAF
genes, with the exception of HT-29 cells that harbor BRAF and
PIK3CA mutations20. KRAS-mutant cell lines exhibited enhanced
KRAS mRNA expression and RAS activity compared to KRAS
wild-type cells (Supplementary Fig. 1a–d). Interestingly, upon
pleural injection to appropriate hosts, all cell lines produced
extensive pleural carcinomatosis, but exclusively KRAS-mutant
cells gave rise to MPE (Fig. 1b–d; Table 1). To deﬁnitely test this
in an isogenic cellular system, we derived lung adenocarcinoma
cell lines from C57BL/6 and FVB mice. For this, C57BL/6 mice
received ten and FVB mice four weekly intraperitoneal injections
of the lung carcinogen urethane (1 g kg 1), as described
elsewhere21,22, and were killed after 10 months, followed
by long-term lung tumour culture in vitro23. The resulting
cell lines (C57BL/6 and FVB-derived urethane-induced lung
adenocarcinoma, CULA and FULA cells, respectively) were
tumourigenic when implanted subcutaneously in syngeneic
mice. Importantly, three different FULA cell lines had three
different Kras mutations (including Q61H, Q61R and G12V
mutations), while CULA cells were Kras wild-type (Fig. 1a;
Table 1). In accordance with the results from existing cell lines, all
Kras-mutant FULA cell lines were MPE-competent, while
Kras-wild-type CULA cells were not (Fig. 1b–d; Table 1). In
summary, out of the 12 different cell lines tested, six out of six
KRAS-mutant cell lines were MPE-competent and none out of six
MPE-incompetent, while none out of six KRAS-wild-type cell
lines was MPE-competent, and six out of six MPE-incompetent
(P¼ 0.0022; w2-test), indicating a statistically signiﬁcant
association between mutant KRAS and MPE.
Myeloid cells in mutant KRAS-dependent MPE. Kras-mutant
tumour cell-triggered MPE was clinically important as mice with
MPE succumbed signiﬁcantly (Po0.0001; log-rank test) earlier
compared with mice with dry pleural carcinomatosis from
Kras-wild-type cells (Supplementary Fig. 1e). In addition to early
lethality, mutant Kras-dependent MPE development was asso-
ciated with a massive inﬂux of myeloid cells into the pleural
space. This was investigated using irradiated C57BL/6 chimeras
reconstituted with luminescent bone marrow from ubiquitously
luminescent CAG.Luc.eGFP donor mice fully backcrossed to the
C57BL/6 strain6,7,24. Fourteen days after pleural tumour cell
injection, only chimeras injected with Kras-mutant tumour
cells showed an increased thoracic bioluminescent signal
(Supplementary Fig. 1f). This KRAS-dependent inﬂammatory
response associated with MPE formation was predominated by
both polymorphonuclear and mononuclear myeloid cells that
expressed both CD11b and Gr1, and either Ly6c or Ly6g
(Fig. 1e,f; Supplementary Figs 1g and 2a). MPE development
triggered by KRAS-mutant cancer cells was associated with an
inﬂux of increased numbers of all kinds of myeloid cells into the
pleural space, but not with the presence of newly-appearing
morphologically or molecularly distinct cell types, since
differential pleural cell counts and ﬂow cytometry results were
similar percentage-wise in mice with or without a MPE
(Supplementary Fig. 2a). In addition to triggering a myeloid
inﬂammatory response, KRAS-mutant pleural tumours and MPEs
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showed enhanced angiogenic and vasoactive potential in several
in vivo assay systems compared with KRAS-wild-type tumours
(Supplementary Fig. 2b–d). However, we did not detect an
increased proliferative or clonogenic capacity speciﬁcally
characterizing KRAS-mutant cells and tumours compared with
KRAS-wild-type ones (Supplementary Fig. 2e–i). This was in
accord with the equal total mass of pleural tumors per mouse
observed across pleural-injected KRAS-mutant and wild-type
tumour cells (Fig. 1b). Collectively, these results suggested that
mutant KRAS-driven MPE is associated with induction of an
inﬂammatory, angiogenic, and vasoactive response in the pleural
space, but not necessarily with enhanced pleural tumour growth.
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Figure 1 | Selective induction of malignant pleural effusions by KRAS-mutant tumour cells. Mutation status of and malignant pleural disease induction
by twelve murine and human tumour cell lines after pleural delivery to appropriate recipient mice. (a) Kras cDNA Sanger sequencing traces of C57BL/6
mouse splenocytes (control) and of ﬁve C57BL/6 mouse tumour cell lines. Black arrows indicate heterozygous missense mutations in Kras codons 12 and
13. (b) Data summary of pleural tumor mass (n¼ 53, 26, 19, 30, 19, 27, 20, 16, 14, 14, 14, and 15, respectively, for LLC, MC38, AE17, B16F10, PANO2, FULA,
CULA, A549, LTP A549, SKMEL2, HT-29, and HEK293T cells). (c) Data summary of malignant pleural effusion (MPE) volume (n¼ 53, 26, 19, 30, 19, 27,
20, 16, 14, 14, 14, and 15, respectively, for LLC, MC38, AE17, B16F10, PANO2, FULA, CULA, A549, LTP A549, SKMEL2, HT-29, and HEK293T cells).
(d) Representative images of MPEs (dashed lines), pleural tumours (t), lungs (l), and hearts (h) imaged through the diaphragm. Scale bars, 1 cm. (e) Data
summary of pleural CD11bþGr1þ cells (n¼ 5–16 animals/group were analysed). (f) Representative dotplots and gating strategy for the quantiﬁcation of
pleural CD11bþGr1þ cells. Data are presented as mean±s.e.m. P, probability values for overall comparisons by one-way ANOVA. * and ***: Po0.05 and
Po0.001 for the comparison between HEK293Tcells and any other cell line (b) or for the comparison between any Kras-mutant and any Kras-wild-type cell
line (c,e) by Bonferroni post-tests. WT, wild-type; LLC, C57BL/6 Lewis lung carcinoma; MC38, C57BL/6 colon adenocarcinoma; AE17, C57BL/6 malignant
pleural mesothelioma; B16F10, C57BL/6 malignant skin melanoma; PANO2, C57BL/6 pancreatic adenocarcinoma; FULA, FVB urethane-induced lung
adenocarcinoma; CULA, C57BL/6 urethane-induced lung adenocarcinoma; A549, human lung adenocarcinoma; LTP A549, long-term passaged A549 cells
having lost the Ychromosome; SKMEL2, human malignant skin melanoma; HT-29, human colon adenocarcinoma; HEK293T, human embryonic kidney cells.
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Mutant KRAS promotes MPE. To corroborate the link between
KRAS mutations and MPE, we undertook both shRNA-mediated
KRAS silencing in cell lines harboring mutant KRAS, as well as
mutant KRAS overexpression in cell lines harboring wild-type
KRAS. Stable transduction of six different Kras-mutant mouse
tumour cells with lentiviral-delivered Kras-speciﬁc shRNA
(shKras) resulted in diminished expression of both murine Kras
isoforms (2A and 2B) and decreased RAS signalling compared
with random (control, shC) shRNA, whereas overexpression of
mutant KrasG12C isoforms in murine and human cell lines
carrying wild-type KRAS via retroviral transduction enhanced the
respective KRAS protein levels and increased RAS signalling
(Supplementary Fig. 3). Manipulation of KRAS signalling did not
result in obvious enhancements of tumour cell proliferation or
survival in vitro; on the contrary, overexpression of KrasG12C2A
in PANO2 cells and of KrasG12C2B in B16F10 cells slowed their
growth rate (Supplementary Fig. 4). However, upon direct
inoculation of all parental and daughter KRAS-modulated cell
lines into the pleural space of appropriate (C57BL/6, FVB or
NOD/SCID) host mice, all mice developed similar extent of
pleural carcinomatosis, but expression of mutant KRAS was a
cardinal determinant of MPE in all cell lines examined (Fig. 2a,b;
Table 2; Supplementary Fig. 5). More speciﬁcally, Kras silencing
universally abrogated MPE formation by LLC, MC38, AE17 and
three different FULA cell lines, that is, in cells harbouring either
KRAS G12C (LLC & AE17 cells), G13R (MC38 cells), G12V,
Q61H or Q61R (FULA cells) mutations, whereas oncogenic
KrasG12C expression conferred MPE competence to B16F10,
PANO2, SKMEL2, and HEK293T cells. Remarkably: (i) expres-
sion of KrasG12C isoform 2A conferred enhanced MPE compe-
tence to PANO2 cells compared with KrasG12C isoform 2B,
although the later was more abundantly expressed by KRAS-
mutant cancer cells; and (ii) mutant KRAS expression converted
even benign HEK293T cells to MPE competence (Fig. 2a,b;
Table 2; Supplementary Fig. 5). Using pleural injection of parental
and KRAS-modulated MC38 and PANO2 cells into C57BL/6
chimeras reconstituted with CAG.Luc.eGFP bone marrow, we
identiﬁed that mutant KRAS is not only responsible for MPE
development, but also for the associated pleural inﬂux of
CD11bþGr1þ cells (Fig. 2c; Supplementary Fig. 5c,d). Taken
together, these results indicated that mutant KRAS is dispensable
for pleural tumour growth, but important for MPE development
and for the associated systemic recruitment of CD11bþGr1þ
myeloid cells, and suggested that KRAS must be responsible for
the secretion of a solute mediator of MPE by tumour cells.
KRAS-mutant tumour cells signal via CCL2 to host cells.
To identify the MPE mediator(s) downstream of mutant KRAS
and to tease out the transcriptional signature of mutant KRAS on
tumour cells, we performed comparative microarray-based
transcriptome proﬁling of Kras-mutant and wild-type mouse
tumour cells versus benign airway cells. Unsupervised clustering
according to global gene expression revealed that Kras-mutant
cell lines clustered closely together (Supplementary Fig. 6a).
Individual gene analysis identiﬁed 25 transcripts overrepresented
more than 10-fold in KRAS-mutant, but not in KRAS-wild-type,
cell lines compared with benign cells (Fig. 3a; Table 3). Micro-
array results were veriﬁed by qPCR and ELISA (Fig. 3b;
Supplementary Figs 6b,c). Furthermore: (i) manipulation of
mutant KRAS expression resulted in parallel changes in Ccl2
expression; (ii) cell culture media conditioned by KRAS-mutant
tumour cells featured markedly elevated CCL2 levels compared
with media conditioned by KRAS-wild-type tumour cells; and
(iii) mice bearing in their pleural space KRAS-mutant tumour
cells featured markedly elevated serum CCL2 levels compared
with mice harbouring KRAS-wild-type tumour cells
(Supplementary Fig. 6d–g). To corroborate CCL2 as the down-
stream effector of mutant KRAS that mediates MPE in vivo, we
directly delivered LLC (KrasG12C), MC38 (KrasG13R), and
PANO2 cells overexpressing KrasG12C isoform 2A into the
pleural space of Ccr2-gene-deﬁcient mice (Ccr2 / ; the gene
encoding the cognate receptor of CCL2)25 and C57BL/6 controls.
In accord with our hypothesis, Ccr2 / mice were protected
against MPE induced by all three Kras-mutant tumour cell lines
and displayed reduced CCR2 expression by pleural ﬂuid cells and
decreased accumulation of CD11bþGr1þ cells in the pleural
space (Fig. 3c; Supplementary Fig. 6h,i). Collectively, these data
suggest that mutant KRAS drives MPE development via systemic
CCL2 signalling to CCR2þ host cells.
Mutant KRAS recruits splenic CD11bþGr1þ cells to MPE.
We next sought to identify the systemic recruitment patterns of
myeloid cells during MPE development. For this, C57BL/6 chi-
meras reconstituted with CAG.Luc.eGFP bone marrow were
inoculated with Kras-mutant pleural tumour cells and were
serially imaged for bioluminescence. Although immediately after
pleural tumour cell delivery the myeloid-emitted bioluminescent
signal was primarily identiﬁed over the hematopoietic bones, it
sequentially translocated to the upper left abdomen (days 10–12
post-tumour cell injection) before appearing in the thorax at days
Table 1 | Incidence of murine malignant pleural effusions and mutation status of twelve tumour cell lines.
n¼265 MPE KRAS EGFR BRAF PIK3CA P value
No Yes %
LLC 1 52 98 G12C WT WT WT 0.0537
MC38 1 25 96 G13R WT WT WT 0.2954
AE17 3 16 84 G12C WT WT WT 1.0000
B16F10 24 6 20 WT WT WT WT 0.000012
PANO2 18 1 5 WT WT WT WT 0.00000064
FULA 3 24 89 G12V/Q61R/H WT WT WT 0.6796
CULA 18 2 10 WT WT WT WT 0.000003
A549 2 14 88 G12S WT WT WT 1.0000
LTP A549 0 14 100 G12S WT WT WT 0.2443
SKMEL2 13 1 7 WT WT WT WT 0.000012
HT-29 13 1 7 WT WT V600E/T119S P449T 0.000012
HEK293T 15 0 0 WT WT WT WT 0.00000044
AE17, C57BL/6 malignant pleural mesothelioma; A549, human lung adenocarcinoma; B16F10, C57BL/6 malignant skin melanoma; CULA, C57BL/6 urethane-induced lung adenocarcinoma; FULA,
FVB urethane-induced lung adenocarcinoma; HT-29, human colon adenocarcinoma; HEK293T, human embryonic kidney cells; LLC, C57BL/6 Lewis lung carcinoma; LTP A549, long-term passaged
A549 cells having lost the Y chromosome; MC38, C57BL/6 colon adenocarcinoma; PANO2, C57BL/6 pancreatic adenocarcinoma; SKMEL2, human malignant skin melanoma; WT, wild-type.
Shown is number of mice (n) that developed dry pleural carcinomatosis (no MPE;o100ml pleural ﬂuid) and number (n) and percentage (%) of mice that developed MPE (Z100 ml pleural ﬂuid).
Po0.0001 for overall comparison by w2-test. P, probability values for comparison with AE17 cells, the KRAS-mutant cell line with the lowest MPE incidence by Fischer’s exact tests.
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12–14 post tumour cell injection (Supplementary Fig. 7a).
Splenectomy abolished this abdominal myeloid-borne signal that
was recapitulated from explanted spleens (Fig. 3d). In addition,
CCR2þCD68þ myeloid cells were identiﬁed in the splenic
marginal zones and the pleural cavities of mice with MPE
induced by KRAS-mutant cells, but not of naive mice
(Supplementary Fig. 7b). These results suggested that CD11bþ
Gr1þ myeloid cells are mobilized by mutant KRAS-driven
CCL2-mediated signalling from the bone marrow to MPE via
the spleen. On the basis of this evidence and the existing
literature26–28, we hypothesized that the splenic passage of
CD11bþGr1þ cells is essential for MPE formation. To test
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Figure 2 | Mutant KRAS promotes malignant pleural effusion development. Impact of shRNA-mediated Kras silencing on MPE competence of cell
lines harboring mutant Kras, and of mutant KrasG12C overexpression in cell lines harboring wild-type KRAS. (a) Data summary of pleural tumor mass
(n¼ 14, 12, 11, 14, 11, 11, 9, 9, 11, 10, 13, 16, 12, 16, 9, 10, 9, and 9, respectively, for LLC shC, LLC shKras, MC38 shC, MC38 shKras, AE17 shC, AE17 shKras,
FULA shC, FULA shKras, B16F10 pC, B16F10 pDKras2A, B16F10 pDKras2B, PANO2 pC, PANO2 pDKras2A, PANO2 pDKras2B, SKMEL2 pC, SKMEL2
pDKras2B, HEK293T pC, and HEK293T pDKras2B cells). (b) Data summary of MPE volume (n¼ 14, 12, 11, 14, 11, 11, 9, 9, 11, 10, 13, 16, 12, 16, 9, 10, 9, and
9, respectively, for LLC shC, LLC shKras, MC38 shC, MC38 shKras, AE17 shC, AE17 shKras, FULA shC, FULA shKras, B16F10 pC, B16F10 pDKras2A, B16F10
pDKras2B, PANO2 pC, PANO2 pDKras2A, PANO2 pDKras2B, SKMEL2 pC, SKMEL2 pDKras2B, HEK293T pC, and HEK293T pDKras2B cells). (c) Data
summary of pleural CD11bþGr1þ cells (n¼ 7–11/group were analysed). Data are presented as mean±s.e.m. P, probability values for overall comparisons
by one-way ANOVA. ns, *, **, and ***: P40.05, Po0.05, Po0.01, and Po0.001 for the comparison between the indicated cell line and the respective
control (c) by Student’s t-test or one-way ANOVA with Bonferroni post-tests, as appropriate.WT, wild-type; shC, random shRNA; shKras, anti-Kras-speciﬁc
shRNA; pC, control (empty) overexpression vector; pDKras2A and pDKras2B, overexpression vectors encoding mutant mouse KrasG12C isoforms A and B,
respectively; WT, wild-type; LLC, C57BL/6 Lewis lung carcinoma; MC38, C57BL/6 colon adenocarcinoma; AE17, C57BL/6 malignant pleural mesothelioma;
B16F10, C57BL/6 malignant skin melanoma; PANO2, C57BL/6 pancreatic adenocarcinoma; FULA, FVB urethane-induced lung adenocarcinoma; SKMEL2,
human malignant skin melanoma; HEK293T, human embryonic kidney cells.
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this, we delivered MC38 cells (KrasG13R) or PANO2 cells
expressing mutant KrasG12C isoform 2A or 2B to the pleural
cavities of splenectomized and sham-operated C57BL/6 mice after
allowing two weeks for recovery. Indeed, splenectomy markedly
protected C57BL/6 mice from MPE, prolonged their survival,
and prevented pleural accumulation of CD11bþGr1þ myeloid
cells (Fig. 3e; Supplementary Fig. 7c,d). Similarly, splenectomy
protected NOD/SCID mice from A549-induced MPE (KRASG12S;
Supplementary Fig. 7e), further suggesting that myeloid and not
lymphoid splenic cells promote MPE in these lymphoid-deﬁcient
mice. Splenectomy-conferred protection was long-lived, as even
mice collected 30 days post-tumour cell injection did not have
MPE (Supplementary Fig. 7c). To address whether splenic
CD11bþGr1þ cells are required for MPE development,
tumour-naive and tumour-bearing CAG.Luc.eGFP mice were
used as splenocyte donors to splenectomized pleural MC38
(KrasG13R)-bearing C57BL/6 mice. These CAG.Luc.eGFP donors
received pleural injections of saline (naive splenocyte), control
shRNA-expressing MC38 cells (MC38 shC-educated splenocyte)
or Kras speciﬁc-shRNA expressing MC38 cells (MC38 shKras-
educated splenocyte) and 13 days later, their spleens were
collected and processed to single-cell suspensions. In parallel,
splenectomized or sham-operated C57BL/6 hosts received pleural
MC38 cell injections. At post-injection day 9, splenectomized
animals received ﬁve million intravenous splenocytes obtained
from naive, shC or shKras MC38-bearing donors whereas, at
post-injection day 13, these mice were analysed for MPE
incidence, volume, survival, and for LucþCD11bþGr1þ
recruited pleural cells (derived from transplanted splenocytes).
Interestingly, only splenocytes from donors inoculated with
MC38 cells bearing intact mutant KRAS signalling were able to
translocate to the pleura and promote MPE formation in
splenectomized mice harbouring pleural MC38 cells
(Supplementary Fig. 7f–h). Taken together, these results
indicated that KRAS-mutant pleural tumours induce the
sequential recruitment of CD11bþGr1þ cells from the bone
marrow to the spleen and into the pleural cavity. Furthermore,
that during MPE formation, bone marrow-borne, splenic
CD11bþGr1þ cells are conditioned by solute mediators
secreted by KRAS-mutant pleural tumours (possibly CCL2) and
functionally contribute to MPE development.
KRASmutations in human MPE. We next Sanger-sequenced the
KRAS transcripts of 12 human MPEs caused by metastatic
lung adenocarcinomas according to established protocols16.
Interestingly, KRAS mutations were present in numerous MPEs,
but were not always readily detectable by automated Sanger
sequencing trace analysis using BioEdit software29, since mutant
base traces were often hidden underneath wild-type traces
superimposed by the other KRAS allele, or by tumour-
inﬁltrating stromal cells (Fig. 4a,b; Table 4). We also analysed
recently published data of the site of recurrence of 481 resected
non-small cell lung cancers according to KRAS and EGFR
mutation status, and found that KRAS mutations overall were
highly signiﬁcantly (Po0.0001; Fischer’s exact test) associated
with pleural recurrence (Table 4). We went on to derive cell lines
from eight patients with lung adenocarcinoma-induced MPE that
were initially tested KRAS wild-type. Interestingly, KRAS
mutations were frequently identiﬁed in MPE cell lines initially
tested
wild-type (Fig. 4c–e; Table 4). These results suggested that:
(i) KRAS mutations are present in a substantial proportion of
patients with lung adenocarcinoma-caused MPE in Europe;
(ii) KRAS mutation frequency may be underestimated in MPE
samples analysed automatically; and (iii) our observations in mice
may also hold true in humans.
Targeting KRAS is effective against MPE development. To
determine the potential efﬁcacy of KRAS inhibition against MPE,
the novel KRAS inhibitor deltarasin30 was administered daily
intraperitoneally at 15mg kg 1, side-by-side with a saline control
treatment, to mice with established pleural tumours. For this,
treatments commenced at day 4–14 post-mouse tumour cell
injections and at day 14 post-human tumour cell injections to
allow initial tumour implantation in the pleural space6,7. At day
13 after pleural injection of MC38 cells (KrasG13R), deltarasin-
treated C57BL/6 mice developed fewer and smaller MPEs,
Table 2 | Incidence of malignant pleural effusions caused by parental and KRAS -modulated tumour cell lines.
n¼206 MPE P value
no yes %
LLC shC (G12C) 3 11 79 c
LLC shKras 10 2 17 0.0048
MC38 shC (G13R) 0 11 100 C
MC38 shKras 10 4 29 0.0005
AE17 shC (G12C) 1 10 91 c
AE17 shKras 11 0 0 o0.0001
FULA shC (G12V, Q61R/H) 1 8 89 c
FULA shKras 8 1 11 0.0034
B16F10 pC (WT) 10 1 9 c
B16F10 pDKras2A 0 10 100 o0.0001
B16F10 pDKras2B 1 12 92 o0.0001
PANO2 pC (WT) 14 2 13 c
PANO2 pDKras2A 0 12 100 o0.0001
PANO2 pDKras2B 4 12 75 0.0010
SKMEL2 pC (WT) 9 0 0 c
SKMEL2 pDKras2B 2 8 80 0.0007
HEK293T pC (WT) 9 0 0 c
HEK293T pDKras2B 2 7 78 0.0023
AE17, C57BL/6 malignant pleural mesothelioma; B16F10, C57BL/6 malignant skin melanoma; FULA, FVB urethane-induced lung adenocarcinoma; HEK293T, human embryonic kidney cells; LLC,
C57BL/6 Lewis lung carcinoma; MC38, C57BL/6 colon adenocarcinoma; PANO2, C57BL/6 pancreatic adenocarcinoma; SKMEL2, human malignant skin melanoma; WT, wild-type.
Shown is number of mice (n) that developed dry pleural carcinomatosis (no MPE;o100ml pleural ﬂuid) and number (n) and percentage (%) of mice that developed MPE (Z100 ml pleural ﬂuid).
Po0.0001 for overall comparison by w2 test. P, probability values for comparison with parental control cells (c) by Fischer’s exact tests.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15205
6 NATURE COMMUNICATIONS | 8:15205 | DOI: 10.1038/ncomms15205 | www.nature.com/naturecommunications
retarded pleural tumour dissemination and decreased pleural
CD11bþGr1þ accumulation compared with controls (Fig. 5a;
Table 5). Furthermore, in vitro treatment of MC38 cells with
deltarasin resulted in almost complete elimination of CCL2
secretion (Fig. 5b). To test the impact of KRAS blockade in a
more human-relevant setting, NOD/SCID mice received
deltarasin and control treatments starting at two weeks after
pleural delivery of one million A549 cells (KRASG12S). At day 30
after tumour cell injection, deltarasin-treated mice had markedly
decreased MPE volume and incidence compared with controls
(Fig. 5c; Table 5). We also explored direct intrapleural targeted
deltarasin delivery against experimental MPE, since chronic
KRAS inhibition may result in marked toxicity. For this, C57BL/6
mice received pleural MC38 cells, followed by a single intrapleural
injection of liposomal-encapsulated deltarasin (15mg kg 1; one
single dose equal to the daily intraperitoneal drug dose
administration) or empty liposomes31,32 on day seven post-
tumour cells. Interestingly, single-dose intrapleural liposomal
deltarasin exhibited equal efﬁcacy with repetitive intaperitoneal
drug treatment, halting both MPE accumulation and
CD11bþGr1þ cell inﬂux (Fig. 5d; Table 5). We ﬁnally cross-
examined the effects of deltarasin and of a well-characterized
neutralizing anti-CCL2 antibody6,7,33,34. For this, C57BL/6 mice
received intrapleural PANO2 cells stably expressing KrasG12C
isoforms 2A or 2B. After 4 or 14 days, respectively, mice started
receiving daily intraperitoneal deltarasin (15mg kg 1) or anti-
CCL2 antibody (50mg kg 1) every 3 days. Control mice received
daily saline injections and IgG2a control antibody (50mg kg 1)
every 3 days. Interestingly, both treatments were equally
effective in reducing MPE incidence and volume, as well as
CD11bþGr1þ cell accumulation (Fig. 5e; Table 5). These
results indicated that deltarasin is effective in halting MPE
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Figure 3 | Mutant KRAS signals via CCL2 to recruit splenic myeloid cells to malignant pleural effusions. (a) Comparative transcriptome analysis of
mouse tumour cell lines with deﬁned Kras mutation status versus benign airway epithelial cells by microarray. Diagram depicting the analytic strategy
employed to identify the transcriptional signature of mutant Kras comprised of 25 genes (top ten shown in table), among which Ccl2 ranked second.
(b) Chemokine protein secretion by parental (white bars: cells stably expressing random shRNA or control overexpression vector) and Kras-modulated (red
bars: cells stably expressing anti-Kras-speciﬁc shRNA; green bars: cells stably expressing vector encoding mutant mouse KrasG12C isoform B) murine cell
lines by ELISA showing transcriptional regulation of CCL2, but not of CXCL1 and CXCL2, by mutant Kras (n¼ 5–7/group). (c) Data summaries of malignant
pleural effusion (MPE) volume (top; LLC: n¼ 9/group; MC38: n¼ 14–15/group; PANO2 pDKras2A: n¼8–18/group) and pleural CD11bþGr1þ cells
(bottom; LLC: n¼9/group; MC38: n¼ 14–15/group; PANO2 pDKras2A: n¼ 5/group) of Ccr2 / and C57BL/6 control mice after intrapleural injection of
three different tumour cell lines. pDKras2A, vector encoding mouse KrasG12C isoform A. (d) Representative bioluminescent images of chimeric C57BL/6
mouse transplanted with bioluminescent bone marrow from CAG.Luc.eGFP donor before and after splenectomy performed at day 13 after intrapleural MC38
cells. Scale bars, 1 cm. (e) Data summaries of MPE volume (top; n¼ 9/group) and pleural CD11bþGr1þ cells (bottom; n¼9/group) of C57BL/6 mice
pretreated with sham surgery or splenectomy followed by intrapleural injection of MC38 cells, or PANO2 cells expressing pDKras2A or pDKras2B two
weeks later. Data are presented as mean±s.d. ns, *, **, and ***: P40.05, Po0.05, Po0.01, and Po0.001 for comparison with parental lines (b), between
the two mouse strains (c), or between different surgeries (e) by Student’s t-test.
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induction by KRAS-mutant tumour cells and suggested that
mutant KRAS-driven MPE in humans may also be actionable.
Discussion
The dichotomous phenotype of primary and metastatic pleural
tumours, some of which are associated with an MPE whereas
others are not, is of paramount clinical importance, and
prompted us to hypothesize that a causative molecular signature
underlines MPE formation2–4. We show that cancer cells bearing
different KRAS mutations cause MPE upon pleural dissemination
and that mutant KRAS is important for experimental MPE
development. Furthermore, that mutant KRAS-driven MPE is
attributed to a CCL2-dependent signalling cascade that is
necessary for the sequential translocation of CD11bþGr1þ
cells from the bone marrow to the spleen and the tumour-
involved pleural cavity, where, in turn, these cells promote MPE
formation. Proof-of-principle clinical data indicate that KRAS
mutations are present in a substantial proportion of MPE patients
in Europe and that they might be underestimated by automated
sequencing analyses. Finally, we show that pharmacologic
interception of this newly identiﬁed KRAS-driven, CCL2-
mediated pathway to MPE can prevent MPE development.
The newly identiﬁed genotype-disease connection between
mutant KRAS and MPE was corroborated using 12 different
isogenic cellular systems of parental and daughter KRAS-
modulated cell lines. In each and single one of these systems,
mutant KRAS was required and sufﬁcient for MPE. Particularly
impressive was the switch of PANO2 cells upon KrasG12C2A
expression from complete MPE incompetence during a month’s
observation to acute and lethal MPE induction within 7 days. The
same is true for benign HEK293T that were rendered MPE-
proﬁcient by isolated expression of KrasG12C2B per se. But is the
proposed mutant KRAS-MPE link clinically relevant? KRAS
mutations are not frequently found in human MPE as opposed to
EGFR and EML4/ALK mutations8–16. First, we believe that KRAS
mutations are not looked for because they are considered not
actionable and mutually exclusive to EGFR mutations, notions
that are currently being revisited8–16,35,36. We show the clinical
data that indicate that KRAS mutations are frequent in European
patients with MPE from lung adenocarcinoma and that they
might be underappreciated. A recent study also showed how
KRAS mutations can be missed in MPE samples, but persist in
cultured cell lines derived from the same patients16, a ﬁnding
recapitulated in patients from our centre. To this end, most MPE
sequencing studies were performed in Asian populations
with high EGFR and EML/ALK and low KRAS mutation
frequencies8–16,35,36. A recent study of European patients with
resected lung tumours clearly showed that KRAS mutations are
linked with pleural spread19. Third, pleural tumours are diffuse-
multifocal and probably multiclonal36 and it is conceivable that
mutant KRAS MPE-initiating cells escape detection in focal
pleural tumour tissue biopsies and low-volume pleural ﬂuid
aspirates.
We do not claim that KRAS mutations are the only ones that
cause MPE in humans and postulate mutant KRAS effects to be
class effects shared by all driver mutations aligned along the
KRAS pathway, including EGFR, KRAS, PIK3CA, BRAF, MET,
EML4/ALK, RET and others. To this end, mutant EGFR was
recently shown to cause MPE when expressed in H1299 human
lung adenocarcinoma cells17. However, possible pathogenic roles
for other lung cancer drivers in MPE remain to be shown.
Together with the advent of MPE sequencing techniques8–16,
such developments could lead to targeted therapies for MPE in
the near future. Moreover, MPE is a clinically heterogeneous set
of diseases from a number of primary sites. KRAS mutations are
more relevant to patients with lung, pancreatic, and colon cancers
and leukaemias. In other tumors (that is, breast cancer) other
Table 3 | Candidate mutant Kras transcriptome signature.
Gene symbol Gene name DGE LLC* DGE MC38* DGE AE17*
Asns Asparagine synthetase þ 12.7 þ 11.6 þ 11.2
Bcat1 Branched chain aminotransferase 1, cytosolic þ 11.2 þ 17.6 þ 12.2
Casp3 Caspase 3 þ 12.7 þ 16.0 þ 17.4
Ccl2 Chemokine (C–C motif) ligand 2 þ85.4 þ 119.3 þ97.7
Ccl7 Chemokine (C–C motif) ligand 7 þ 11.3 þ 14.4 þ 17.8
Cep170 Centrosomal protein 170 þ 15.3 þ 11.6 þ 13.5
Dab2 Disabled 2, mitogen-responsive phosphoprotein þ 12.7 þ 18.2 þ 10.4
Dusp9 Dual speciﬁcity phosphatase 9 þ 13.1 þ 15.5 þ 17.0
Gm10717 Predicted gene 10717 þ 10.9 þ 33.3 þ45.6
Gm10721 Predicted gene 10721 þ 10.9 þ 15.1 þ 31.4
Gm10722 Predicted gene 10722 þ 15.2 þ 241.9 þ60.5
Gm26523 Predicted gene, 26523 þ 56.3 þ 52.0 þ 36.4
Gpr149 G protein-coupled receptor 149 þ 33.1 þ 33.9 þ 12.5
Hist1h1b Histone cluster 1, H1b þ42.9 þ 50.3 þ48.2
Hjurp Holliday junction recognition protein þ 10.3 þ 14.4 þ 11.3
Lhfp Lipoma HMGIC fusion partner þ 24.9 þ 27.2 þ 23.5
Mpp1 Membrane protein, palmitoylated þ 10.6 þ 16.3 þ 21.3
Nid1 Nidogen 1 þ 13.6 þ 16.0 þ 15.0
Nid1 Nidogen 1 þ 10.3 þ 15.2 þ 11.3
Prrx1 Paired related homeobox 1 þ 27.5 þ 26.9 þ 23.9
Prune2 Prune homolog 2 (Drosophila) þ 24.5 þ 17.5 þ 27.0
Psat1 Phosphoserine aminotransferase 1 þ 12.3 þ 13.3 þ 11.1
S100a4 S100 calcium binding protein A4 þ 13.4 þ 12.5 þ 10.1
Slc30a4 Solute carrier family 30 (Zinc transporter), member 4 þ 20.6 þ 11.7 þ 16.2
Snora17 Small nucleolar RNA, H/ACA box 17 þ 18.3 þ 11.5 þ 26.6
The 25 transcripts identiﬁed from comparative analyses of global gene expression between ﬁve murine cancer cell lines (LLC, MC38, AE17, B16F10, and PANO2 cells) and benign airway epithelial cells by
alphabetic order.
*DGE, fold-difference in gene expression between Kras-mutant tumour cells and benign airway epithelial cells. Ccl2 was the most consistently over-represented transcript across all three cell lines
examined. LLC, C57BL/6 Lewis lung carcinoma; MC38, C57BL/6 colon adenocarcinoma; AE17, C57BL/6 malignant pleural mesothelioma.
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mutations may be functionally involved in MPE formation
(that is, HER2), a postulation that awaits experimental
conﬁrmation. To this end, future human studies aimed at
identifying genotype–phenotype linkages in various tumours
need to be tailored appropriately and need not rely on cross-
sectional frequency observation design. Prospectively genotyped,
case-matched, and longitudinally observed patient cohorts are
more likely to give answers to questions such as the KRAS-MPE
link proposed here.
In addition to the novel cancer genome-phenotype association,
we further show here that mutant KRAS-driven MPE is mediated
via CCL2-dependent paracrine signalling to CD11bþGr1þ
myeloid cells. The well-studied cell-autonomous effects of mutant
KRAS conferring addictive proliferation advantages to the
tumour cell35,37 may be complemented by this paracrine axis
and may temporally precede its clinical manifestation, since
mutant KRAS likely promotes pleural metastasis prior to MPE
development18,19. As opposed to neutrophil chemoattractants
such as CXCL1, CXCL2 (ref. 25), tumour-elaborated CCL2 is a
potent monocyte/macrophage mobiliser promoting angiogenesis
and metastasis34,38 and was identiﬁed here as the transcriptional
target of mutant KRAS in tumour cells. This ﬁnding complements
previous observations implicating CCL2 in mutant KRAS-driven
inﬂammation in the lung epithelium39 and in MPE formation5,6.
Interestingly, mutant HRAS also induces IL-8 signalling40 and the
results imply that different RAS proteins may control distinct
chemokine repertoires in order to mobilize deﬁned myeloid cell
subsets to tumour sites.
Our present and previous ﬁndings5–7 indicate that pleural
tumour-originated CCL2 mobilizes two distinct cell populations
from the bone marrow: mast cells and CD11bþGr1þ cells41,42,
both known to respond to CCL2 (refs 7,25), to facilitate breast
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Figure 4 | KRASmutations in human malignant pleural effusions. (a–c) Sanger sequencing results of human malignant pleural effusions (MPE) caused by
metastatic lung adenocarcinomas from Institution 1. (a) Partial sequence of Homo Sapiens KRAS isoform b transcript showing start codon (green box) and
missense mutations identiﬁed (grey boxes and callouts). Red and blue fonts indicate, respectively, known pathogenic mutations and mutations of unknown
signiﬁcance based on COSMIC20. (b) Partial Sanger-sequencing traces from two patients showing corresponding sequences of patient with wild-type KRAS
alleles and of another with four different KRAS mutations. Arrows indicate missense mutations of pathogenic (red) and unknown (blue) signiﬁcance based
on COSMIC20, as well as nonsense mutations (grey). Note that mutant KRAS traces hide under wild-type traces superimposed by wild-type KRAS alleles
and/or by RNA from tumour or MPE-inﬁltrating benign somatic cells. Importantly, some mutations were not detected by the analysis software (see letters
above mutant trace). Note also multiple mutations in the same patient suggesting a possible multiclonal origin of this MPE. (c–e) Patient-derived MPE cell
line isolation from eight patients from Institution 1 that were initially tested KRAS wild-type. (c) Arrow shows focal clonal expansion of cultured MPE cells
that gave rise to cell line PB-183. Scale bars, 50mm. (d) PB-183-induced tumour in NOD/SCID mouse four weeks after subcutaneous injection of a million
cells (n¼ 5). Scale bar, 1 cm. (e) Partial Sanger-sequencing traces of KRAS cDNA from the initial MPE cells and from two MPE-derived cell lines indicate
KRAS mutations (red arrows and fonts) that were not identiﬁed in the initial samples. Note that even in MPE cell lines mutant KRAS traces hide under
wild-types traces superimposed by wild-type alleles. Again, the mutation was not detected by the software (see letters above mutant trace).
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cancer metastasis to the lungs34, and to sustain tumour growth by
promoting angiogenesis28. CD11bþGr1þ cells were previously
identiﬁed in MPE42 along with mast cells that were shown to
promote MPE by fostering tumour growth and vascular
permeability7. Here we show that the spleen is an important
intermediate organ for MPE development, similar to other
tumour models, with its marginal zone functioning as a reservoir
for bone-marrow-derived CD11bþGr1þ cell progenitors that
are subsequently rapidly deployed to tumour sites43,44. Our
experiments, in line with the work of others26–28,43,44 incriminate
the spleen as a pro-tumour organ and suggest that the splenic
environment is essential for CD11bþGr1þ cell recruitment to
MPE. As splenectomy provided marked protection to mice
against incipient MPE, splenectomy at the time of pleurodesis or
catheter placement may yield considerable beneﬁt to patients with
MPE, a notion worth exploring.
Finally, we present evidence that mutant KRAS-mediated MPE
is actionable by the novel inhibitor of KRAS membrane transport
deltarasin, lending hope for clinical targeting of the oncogene in
the future30,35. Importantly, a CCL2 neutralizing antibody6,7,33,34
was as effective as deltarasin, strengthening the KRAS-CCL2
connection and indicating that intercepting downstream of
mutant oncogene targets may be an alternative to their direct
targeting. In addition to the clinical signiﬁcance of KRAS and
other driver mutations of lung and other cancers in MPE that
needs to be established, open questions that remain include
whether the hypoxic pleural environment impacts MPE
development and whether it triggers phenotypic changes in
pleural metastasized tumour cells, including the KRAS/CCL2 axis
reported here.
In summary, we show that KRAS mutations are causally linked
with MPE in mice. We also show that this link rests on a deﬁned
innate immune response and that it might be at play in humans
with the condition. We believe that this work opens up avenues of
potential progress towards aetiologic MPE therapy, by providing
preclinical proof-of-concept data on immediate and feasible
targeted interventions, such as splenectomy and KRAS and CCL2
blockade, which could provide meaningful beneﬁts to patients
with MPE in the future.
Methods
Study approval. Human MPE samples from twenty patients with lung adeno-
carcinoma-associated MPE from Institution 1 were obtained and biobanked
according to a prospectively placed, standardized and Institutional Ethics
Committee-approved protocol (approval number 22699/21.11.2013) that abides by
the Declaration of Helsinki. Written informed consent was obtained from each
patient. Mouse experiments were carefully designed and were prospectively
approved by the Veterinary Administration of the Prefecture of Western Greece
(protocol approval numbers 3741/16.11.2010, 60291/3035/19.03.2012, and 118018/
578/30.04.2014), and were conducted according to Directive 2010/63/EU
(http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:
0079:EN:PDF).
Reagents. Evans’ blue and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay powder were from Sigma-Aldrich (St Louis, MO); D-luciferin
was from Gold Biotechnology (St Louis, MO); Mouse Gene ST2.0 microarrays and
relevant reagents were from Affymetrix (Santa Clara, CA); murine CCL2, CXCL1,
and CXCL2 and human CCL2 ELISA kits were from Peprotech EC (London, UK);
Table 4 | KRAS mutations in human malignant pleural effusions.
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n (%) Bulk MPE RNA 
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KRAS MUT 0 5
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n(%) WT EGFR MUT KRAS MUT P 
Bone 57(12) 0(0) 61(13) 1.0000
Liver 39(8) 8(2) 9(2) < 0.0001
Brain 26(5) 16(3) 9(2) < 0.0001
Pleura 37(8) 2(0) 89(19) 0.0039 
Lung 89(19) 1(0) 22(5) < 0.0001
Adrenal 10(2) 0(0) 6(1) < 0.0001
1.0000 < 0.0001 < 0.0001
n (%) KRAS WT KRAS MUT
Pleura 39(8) 89(19) 
Other 246(51) 107(22) 
MPE, malignant pleural effusions; MUT, mutant; WT, wild type.
Present study: top—incidence and type of KRAS mutations detected in 12 human MPE caused by metastatic lung adenocarcinomas from Institution 1. Bottom—summary of KRAS mutations of MPE cell
lines isolated from eight patients from Institution 1 that were initially tested KRAS wild-type versus corresponding MPE samples. P¼0.0256 by Fischer’s exact test.
Renaud et al.19: site of recurrence of 481 patients with resected non-small-cell lung cancer according to mutation status19 shows increased pleural dissemination rates in patients with KRAS-mutations.
Top—metastatic site by genotype. Po0.0001 by w2-test. P values for comparison with bone metastases or WT tumours by Fischer’s exact tests. Bottom: pleural versus any other metastatic site by KRAS
genotype. Po0.0001 by Fischer’s exact test.
n(%), of patients.
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Figure 5 | Mutant KRAS-mediated malignant pleural effusions are actionable. (a) C57BL/6 mice received pleural MC38 cells (DKrasG13R), were allowed
seven days for pleural tumour development, and were randomized to daily intraperitoneal saline (100ml) or deltarasin (15mg kg 1) treatments. Shown are
data summaries of malignant pleural effusion (MPE) volume and CD11bþ r1þ cells (both n¼ 8/group), representative images of pleural effusions (dashed
lines) and tumours (t), and representative dotplots of CD11bþGr1þ cells (polygon gates) at day 13 post-MC38 cells. Scale bars, 1 cm. (b) MC38 cells
were treated in vitro with saline or deltarasin (15mgml 1). Shown is CCL2 secreted at 24 h (n¼ 5/group). (c) NOD/SCID mice received pleural LTP A549
cells (DKRASG12S), were allowed 14 days for pleural tumour development, and were randomized to daily intraperitoneal saline (100ml) or deltarasin
(15mg kg 1) treatments. Shown is data summary of MPE volume at day 30 post-tumour cells. (d) C57BL/6mice received pleural MC38 cells followed by a
single intrapleural injection of liposomes containing 1% DMSO or 15mg kg 1 deltarasin in 1% DMSO at day 7 post-tumour cells. Shown are representative
images of pleural effusions (dashed lines) and tumours (t), and data summaries of MPE volume (n¼ 15–16/group) and CD11bþGr1þ cells (n¼ 9/group)
at day 13 post-MC38 cells. Scale bars, 1 cm. (e) C57BL/6mice received pleural PANO2 cells stably expressing mutant Kras vectors (pDKras2A or pDKras2B),
were allowed 4 or 14 days, respectively, for pleural tumour development and were then randomized to intraperitoneal treatment with daily saline plus IgG2a
antibody every three days (50mg kg 1 in 100ml saline), daily deltarasin (15mg kg 1 in 100 ml saline), or anti-CCL2 antibody every three days (50mg kg 1
in 100ml saline). Shown are data summaries of MPE volume (n 27, 10, and 20 mice/group, respectively) and CD11bþGr1þ cells (n¼ 24, 8, and 14/group,
respectively) at day 14 post-tumour cells. Data are presented as mean±s.d. ns, *, **, and ***: P40.05, Po0.05, Po0.01, and Po0.001 for the indicated
comparisons by Student’s t-test (a-d) or one-way ANOVA with Bonferroni post-tests (e).
Table 5 | Incidence of malignant pleural effusions in KRAS-targeted mice.
Treatments No
MPE
MPE P value
Experiment from Fig. 5a MC38-induced MPE daily intraperitoneal treatments
installed at day 7 post-MC38 cells
Saline (100ml) 1 7 —
Deltarasin (15mg kg 1 in 100ml saline) 7 1 0.0101
Experiment from Fig. 5c LTP A549-induced MPE daily intraperitoneal treatments
installed at day 14 post-MC38 cells
Saline (100ml) 0 10 —
Deltarasin (15mg kg 1 in 100ml saline) 5 4 0.0108
Experiment from Fig. 5d MC38-induced MPE once intrapleural treatment at day 7
post-MC38 cells 100 ml injectate volume
Liposomes (saline 1% DMSO) 2 14
Liposomes (15mg kg 1 deltarasin in
saline 1% DMSO
8 7 0.0151
Experiment from Fig. 5e PANO2 pDKras2A/2B-induced MPE intraperitoneal
treatments installed at day 4 or 14 days post-tumour cells, respectively
Daily saline (100ml)þ IgG2a every three
days (50mg kg 1 in 100ml saline)
0 27 —
Daily deltarasin (15mg kg 1 in 100ml
saline)
3 7 0.0157
a-CCL2 every 3 days (50mg kg 1 in
100 ml saline)
14 6 o0.0001
CCL, C–C motif chemokine ligand; DMSO, dimethyl sulfoxide; LTP A549, long-term passaged A549 cells having lost the Y chromosome; MC38, C57BL/6 colon adenocarcinoma; MPE, malignant pleural
effusion; PANO2, C57BL/6 pancreatic adenocarcinoma; D, mutant.
MPE incidence of C57BL/6 mice that received KRAS-mutant pleural tumour cells followed by deltarasin or anti (a)-CCL2 treatments. Shown are numbers of mice (n) and probability (P) values for
comparison with controls by Fischer’s exact test. Po0.0001 for overall comparison of experiment from Fig. 5e by w2-tests.
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primer sets and antibodies are listed in Supplementary Tables 1 and 2, respectively;
RAS activation assay was from Merck Millipore (Darmstadt, Germany); deltarasin
was from MedChem Express (Princeton, NJ) and from Cayman Europe
(Tallinn, Estonia); anti-mouse CCL2 neutralizing antibody, as well as IgG2a control
antibody were from Oncology Discovery Research, Janssen R&D LLC
(Radnor, PA)33,34; 1, 2-Distearoyl-sn-glycero-3-phosphocholine,
phosphatidylglycerol and cholesterol were from Avanti Polar Lipids, Inc.
(Alabaster, AL).
Mice. C57BL/6 (#000664), NOD/SCID (#001303), CAG.Luc.eGFP (#008450), and
Ccr2 / (#004999) mice from Jackson Laboratories (Bar Harbor, ME) were bred
in the University of Patras Center for Animal Models of Disease. All experiments
entailing murine cell lines were done using mice on the C57BL/6 background or
CAG.Luc.eGFP mice backcrossed 4F12 to the C57BL/6 background. All experi-
ments entailing human cell lines were done using mice on the NOD/ShiLtJ back-
ground. Nine hundred and seventy-ﬁve sex-, weight (20–25 g)- and age (6–12
week)-matched male and female (50% of mice from each sex were enrolled in each
experimental arm) experimental mice were used for these studies. The exact animal
numbers per experiment are given in Tables 1, 2 and 5 and in the Legends to
Figures.
Cells. C57BL/6 mouse B16F10 skin melanoma and PANO2 pancreatic and Lewis
lung carcinomas (LLC), as well as human SKMEL2 skin melanoma, A549 lung and
HT-29 colon adenocarcinomas were from the National Cancer Institute Tumour
Repository (Frederick, MD); human HEK293T embryonic kidney cells were from
the American Type Culture Collection (Manassas, VA); C57BL/6 mouse MC38
colon adenocarcinoma cells were a gift from Dr Barbara Fingleton (Vanderbilt
University, Nashville, TN, USA)6,7,45, C57BL/6 mouse AE17 malignant pleural
mesothelioma cells from Dr Y.C. Gary Lee (University of Western Australia, Perth,
Australia)46, and human LTP A549 cells that have suffered chromosome Y loss
from Dr Haralabos P. Kalofonos (University of Patras, Greece). Primary lung
adenocarcinoma cells from C57BL/6 and FVB mice (CULA and FULA cells,
respectively) were generated as described elsewhere23. Brieﬂy, C57BL/6 and FVB
mice received ten and four consecutive weekly intraperitoneal injections of
urethane (1 g kg 1) and were killed ten months later. Lung tumours were isolated
under sterile conditions, strained to single cell suspensions, and cultured for4100
passages over two years. Primary airway cells were derived by culturing stripped
murine tracheal epithelium. Cell lines were authenticated annually using the short
tandem repeat method, microarray, and Sanger sequencing and were tested for
Mycoplasma Spp. biannually by PCR using designated primers (Supplementary
Table 1). All cell lines were cultured at 37 C in 5% CO2-95% air using full culture
medium (DMEM supplemented with 10% FBS, 2mM L-glutamine, 1mM
pyruvate, 100Uml 1 penicillin, and 100mgml 1 streptomycin). For in vivo
injections, cells were collected with trypsin, incubated with Trypan blue, counted
by microscopy in a haemocytometer, their concentration was adjusted in PBS, and
cell were injected through a left intercostal space or in the skin, as described
elsewhere5–7. Only 95% viable cells were used for in vivo injections.
Sequencing plasmids and microarrays. Total cellular RNA was isolated using
Trizol (Invitrogen, Thermo Fisher Scientiﬁc, Waltham, MA) followed by RNAeasy
column puriﬁcation and genomic DNA removal (Qiagen, Hilden, Germany). One
mg puriﬁed total RNA was reverse transcribed using an Oligo(dT)18 primer and
Superscript III (Invitrogen, Thermo Fisher Scientiﬁc, Waltham, MA) according to
the manufacturer’s instructions. For sequencing reactions, Kras, Egfr, Braf and
Pik3ca cDNAs (or parts of these cDNAs) were ampliﬁed in PCR reactions using the
corresponding primers (Supplementary Table 1) and Phusion Hot Start Flex
polymerase (New England Biolabs, Ipswich, MA). cDNA fragments were puriﬁed
with NucleoSpin gel and PCR clean-up columns (Macherey-Nagel, Du¨ren,
Germany) and were directly Sanger-sequenced with their corresponding forward
and reverse primers by VBC Biotech (Vienna, Austria). For RNA interference, the
following proprietary lentiviral shRNA pools of three were obtained from Santa
Cruz Biotechnology (Palo Alto, CA): random control shRNA (shC, sc-108080-V),
GFP control (sc-108084-V), and anti-Kras.shRNA (shKras, sc-33876-V). Anti-Kras
lentiviral shRNA target sequences were: 50-CTACAGGAAACAAGTAGTA-30 ,
50-GAACAGTAGACACGAAACA-30 and 50-CCATTCAGTTTCCATGTTA-30 .
For this study, the following new plasmids were constructed in-house and were
deposited with Addgene (https://www.addgene.org/Georgios_Stathopoulos/),
accompanied by their full sequence ﬁles: (i) a pMIGR1-based puromycin resistance
bicistronic retroviral expression vector (Addgene ID 64335) was constructed by
replacing the eGFP sequences of pMIGR1 vector downstream of IRES with pur-
omycin resistance sequences; (ii) a pMIGR1-based hygromycin resistance bicis-
tronic retroviral expression vector (Addgene ID 64374) was constructed by
replacing the eGFP sequences of pMIGR1 vector downstream of IRES with
hygromycin resistance sequences. Both puromycin and hygromycin resistance
genes were subcloned by restriction enzymes from available construct; (iii) the
derivatives of these vectors, namely eGFP.retro.puro (Addgene ID 64336),
eGFP.retro.hygro (Addgene ID 64375), eGFP.KRASwt-2B retro.puro (Addgene ID
64371), eGFP.KRASG12C-2B.retro.puro (Addgene ID 64372), eGFP.KRASG12C-
2B.retro.hygro (Addgene ID 64376), eGFP.KRASG12C-2A.retro.puro (Addgene ID
64373). Murine KrasG12C isoform 2A and 2B cDNAs were ampliﬁed using a ﬁrst
stand synthesis reverse transcription reaction from 1 mg total LLC RNA using
speciﬁc primers (Supplementary Table 1) and Phusion Hot Start Flex polymerase
(New England Biolabs, Ipswich, MA). Similarly, wild type Kras2B cDNA was
ampliﬁed using a ﬁrst stand synthesis reverse transcription reaction from 1 mg total
PANO2 cellular RNA.The corresponding cDNAs were cloned into a peGFP.C1
vector (Clontech, Mountain View, CA) between BglII and EcoRI restriction sites,
in-frame with eGFP and were veriﬁed by sequencing. The eGFP, as well as the wild
type eGFP.KRAS2B and mutant eGFP.KRASG12C2A and 2B-encoding sequences
were restricted out from the corresponding peGFP.C1-based constructs described
above using enzymes AgeI and SmaI, were gel puriﬁed, and were subcloned into
the (AgeI/HpaI-restricted) retroviral bicistronic expression vectors upstream of
IRES-puromycin (ID 64336) and/or IRES-hygromycin (ID 64375) resistance genes,
respectively. Retroviral particles were obtained by transfecting a 3mm well of
conﬂuent HEK293T cells with the desired bicistronic retroviral vectors
(expressing either eGFP or wild type or mutant eGFP.KRAS) along with VSV-G
envelope expressing plasmid pMD2.G (Addgene ID12259) and pCMV-Gag-Pol
expressing the retroviral structure proteins (Cell Biolabs Inc, San Diego, CA) at
1.5:1:1 mass stoichiometry via the CaCl2/BES method. After two days, the cultured
medium (2ml for each retroviral type) was collected and passed through a 45 mM
ﬁlter to remove cellular debris. This supernatant material was supplemented with
8ml medium and was subsequently overlaid on a 100mm plate containing 70%
conﬂuent mouse cancer cells. After 48 h, the medium was removed and the cells
were incubated with selection medium (full cell culture medium supplemented
with either 2–10 mgml 1 puromycin or 50–100 mgml 1 hygromycin). Stable
clones were selected and subcultured. All other cell lines were transfected with
standard DNA amounts using X-Fect (Clontech, Mountain View, CA).
Mouse experiments. Experimental pleural carcinomatosis was induced by pleural
delivery of 1.5 105 murine cancer cells, 106 human cancer cells or 3 106
HEK293T cells. MPE models and splenectomy have been described elsewhere5–7.
For bioluminescence imaging, mice were serially imaged on a Xenogen Lumina II
and data were analysed using Living Image v.4.2 (Perkin-Elmer, Waltham, MA),
after delivery of 1mg intravenous D-luciferin (Gold Biotechnology, St Louis, MO)
by retro-orbital injection. For splenocyte give-back, spleens were removed under
sterile conditions from CAG.Luc.eGFP donors (n¼ 3 per group), 13 days after
intrapleural injection with saline or tumour cells. Single-cell suspensions were
prepared by passing spleens through 70 mm nylon cell strainers (BD Biosciences,
Bedford, MA), followed by delivery of 100ml saline containing 5 106 splenocytes
to splenectomized hosts.
Mouse models. For induction of malignant pleural carcinomatosis with or
without a MPE, mice were anaesthetized using isoﬂurane inhalation and received
intrapleural injections of 100 ml PBS containing 150,000 murine, 1,000,000 human
cancer cells or 3,000,000 HEK293T cells. Mice were killed when moribund for
survival and pleural ﬂuid and tumour analyses. Mice with pleural ﬂuid volume
Z100ml (equals the initial injection volume) were judged to have a MPE
(‘wet’ pleural metastasis, that is, active pleural ﬂuid exudation) and were subjected
to pleural ﬂuid aspiration, whereas animals with pleural ﬂuid volumeo100 ml were
judged not to have a MPE (‘dry’ pleural carcinomatosis) and were subjected to
pleural lavage. For this, 1ml normal saline was injected intrapleurally and was
withdrawn after 30 s. Following pleural ﬂuid or lavage retrieval, the chest was
opened and pleural tumours were stripped and weighed. For subcutaneous tumour
formation, mice received 1,000,000 subcutaneous cancer cells and were followed
longitudinally. Three vertical tumour dimensions (d1, d2 and d3) were monitored
serially and tumour volume was calculated using the formula p d1 d2 d3/6.
Both models have been described elsewhere5–7.
Cytology histology and microscopy. Before further processing, MPE ﬂuids were
subjected to red blood cell lysis in ten-fold excess red blood cells lysis buffer
(155mM NH4Cl, 12mM NaHCO3, 0,1mM EDTA). Total pleural cell counts were
determined microscopically on a haemocytometer and cytocentrifugal specimens
(5 104 cells each) of total pleural ﬂuid cells (or of CD45þCD11bþGr1þ sorted
cells) were ﬁxed with methanol for 2min. Cells were stained with May–Gru¨nwald
working solution (May–Gru¨nwald stain in 1mM Na2HPO4, 2.5mM KH2PO4,
pH¼ 6.4) for 6min, then with Giemsa working solution (Giemsa stain in 2mM
Na2HPO4, 5mM KH2PO4, pH¼ 6.4) for 40min, then washed with H2O, and dried.
Slides were mounted with Entellan (Merck Millipore, Darmstadt, Germany) and
coverslipped and were microscopically analysed. For ﬂow cytometry and ﬂuores-
cence-activated cell sorting (FACS) staining, 106 nucleated pleural ﬂuid cells
suspended in 50 ml FACS buffer (PBS supplemented with 2% FBS and 0,1% NaN3)
were stained with the indicated antibodies according to manufacturer’s instructions
(Supplementary Table 2) for 20min in the dark, were washed with FACS buffer
from excess antibody, and were resuspended in 1ml FACS buffer for further
analysis. Spleens ﬁxed in 10% formaldehyde overnight were embedded in parafﬁn
and stored at room temperature. Five-micrometre parafﬁn sections were mounted
on glass slides. Pleural tumours ﬁxed in 10% parafﬁn or in 4% paraformaldehyde
overnight were embedded in parafﬁn or in optimal cutting temperature
(OCT; Sakura, Tokyo, Japan) and were stored at room temperature or  80 C,
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respectively, till further analyses. Five-micrometre-thick parafﬁn or 10-mm-thick
cryosections were mounted on glass slides. Sections were labelled using the indi-
cated antibodies (Supplementary Table 2) and were counterstained with Hoechst
33258 or with Envision colour development system (Dako, Carpinteria, CA).
Immunoreactivity was quantiﬁed as described previously5–7. Bright-ﬁeld and
ﬂuorescent microscopy were carried out using either an AxioObserver D1
inverted microscope (Zeiss, Jena, Germany) or an SP5 confocal microscope
(Leica, Heidelberg, Germany).
Flow cytometry and cell sorting. A CyFlow ML instrument with FloMax Soft-
ware (Partec, Mu¨nster, Germany) was used for cell cytometry, sorting, and data
analysis. CD45þCD11bþGr1þ cells were identiﬁed, enumerated by true
volumetric counting, and their total numbers were calculated as fraction of total
MPE cell counts, or were sorted and collected in FACS buffer at 5 104 cells per ml.
Cellular assays. In vitro cancer cell proliferation was determined using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. For
this, 2 104 cells per well were plated onto 96-well plates. Daily thereafter, 15 ml of
5mM MTT working solution in PBS was added to wells to be measured that day.
The plate was incubated for 4 h at 37 C in a 5% CO2 humidiﬁed incubator fol-
lowed by addition of 100ml acidiﬁed isopropanol per well for sediment solubili-
zation and absorbance measurement at 492 nm on a MR-96A photometer
(Mindray, Shenzhen, China). For soft agar colony formation assay, 7.5 103 cells
were plated in 60mm culture vessels in semi-solid 0.7% agarose in full culture
medium and were incubated for 30 days at 37 C in a 5% CO2 humidiﬁed
incubator. 2ml fresh culture medium was added to each vessel biweekly. After
incubation, 500 ml MTT working solution was added to each vessel and plates were
dried, inverted, photographed and colonies were counted.
Vascular permeability assays. Mice with MPE received 0.8mg intravenous
Evans’ blue and were killed after 1 h for determination of MPE levels of the
albumin-binding dye5–7. Intradermal injections of 50 ml cell-free pleural lavage or
MPE were performed at different spots of the shaved dorsal mouse skin followed
immediately by Evans’ blue injections as above, and euthanasia, skin inversion and
imaging after one hour. The surface area of dye leak was determined using Fiji
academic freeware (http://ﬁji.sc/Fiji), as described elsewhere5–7.
Chick chorioallantoic membrane assay. Fertilized White Leghorn chicken eggs,
as soon as embryogenesis started, were placed for incubation under constant
humidity at 37 C. On day 4, a square window was opened in the shell and then
sealed with adhesive tape. On day 9, a 1 cm2 rubber O-ring was placed on the
surface of the CAM and 50ml PBS or cell-free MPE or pleural lavage supernatants
were added inside the ring’s restricted area. After 48 h, CAM tissues were ﬁxed
in Carson’s solution (saline-buffered formalin) and angiogenesis was evaluated
using Fiji.
Real-time quantitative PCR and microarray hybridization and analysis. qPCR
was performed using ﬁrst strand synthesis reactions along with the indicated
primers and KAPA SYBR FAST qPCR Kit (Kapa Biosystems, Wilmington, MA) in
a StepOne cycler (Applied Biosystems, Carlsbad, CA). The CT values from tri-
plicate qPCR reactions were extracted from the StepOne cycler (Applied Biosys-
tems, Carlsbad, CA) onto Excel spreadsheets and were analysed with the relative
quantiﬁcation method 2–DDCT. The expression level of a given mRNA per sample/
condition was determined relatively to reference gene mRNA levels. For micro-
array, triplicate cultures of 106 cells (for each cell line/condition) were subjected to
RNA extraction as above. Five mg of pooled total RNA were tested for RNA quality
on an ABI2000 bioanalyser (Agilent Technologies, Sta. Clara, CA), labelled, and
hybridized to GeneChip Mouse Gene 1.0 or 2.0 ST arrays according to manu-
facturer’s instructions (Affymetrix, Sta. Clara, CA). For microarray analysis, the
Affymetrix Expression Console was used (parameters: annotation conﬁdence, full;
summarization method: iter-PLIER include DABG; background: PM-GCBG;
normalization method: none), followed by normalization of all arrays together
using a Lowess multi-array algorithm. Intensity-dependent estimation of noise was
used for statistical analysis of differential expression. Unsupervised hierarchical
clustering of microarray data and Venn diagrams were performed using the
MatLab 2014 program. Microarray data are publicly available at the GEO database
(http://www.ncbi.nlm.nih.gov/geo/; Accession ID: GSE58190 and GSE85021).
RAS activation assay and immunoblotting. Total protein extracts were prepared
by lysing 107 cultured cells in Mg2þ Lysis/Wash buffer (25mM HEPES pH¼ 7.5,
150mM NaCl, 1% NP-40, 10mM MgCl2, 1mM EDTA, 2% glycerol). RAS acti-
vation assay was performed with RAS Activation Assay Kit (Merck Millipore,
Darmstadt, Germany) by incubating total cell lysates with Raf-1 Ras-Binding
Domain (RBD)-coated agarose beads according to the manufacturer’s instructions.
Total protein extracts and Raf-1 RBD agarose bead samples were analysed using
6–20% SDS–PAGE followed by standard blotting to PVDF membranes
(Merck Millipore, Darmstadt, Germany). Membranes were incubated with primary
antibodies, followed by incubation with the appropriate HRP-conjugated second-
ary antibodies at the manufacturers’ indicated dilutions (Supplementary Table 2),
and were visualized by chemiluminescence ﬁlm exposure, using the enhanced
chemiluminescence substrate (Merck Millipore, Darmstadt, Germany). Full
uncropped immunoblots are shown in Supplementary Figures 8–10.
Enzyme-linked immunosorbent assays (ELISA). CCL2, CXCL1 and CXCL2
levels of cell culture supernatants, as well as CCL2 levels of cell-free MPE and
corresponding sera were determined using dedicated murine and human ELISA
kits according to the manufacturer’s instructions (Peprotech, London, UK and
R&D, Minneapolis, MN).
Bone marrow transplantation. For adoptive bone marrow replacement, C57BL/6
hosts received ten million intravenous bone marrow cells ﬂushed from the femurs and
tibias of CAG.Luc.eGFP donors, 12h after total-body irradiation (1,100 rad), as described
elsewhere6,7. One mouse in each experiment was not engrafted (sentinel) and was
observed till moribund between days 5 and 15 post-irradiation. The mice were left to
recover at least for one month before subjecting them to experimentally induced MPE.
Liposome preparation and physicochemical characterization. Deltarasin-
encapsulating liposomes were prepared by the DRV technique as described else-
where31,32 by freeze drying 30mg of empty DSPC/PG/Chol (9:1:5 (mol:mol:mol))
unilamelar sonicated vesicles with 1ml of deltarasin solution (5mgml 1) in PBS,
or plain PBS (for empty liposomes), followed by controlled re-hydration. The
liposome size was decreased by extrusion though Lipo-so-fast extruder,
polycarbonate membranes (Avestin Europe) with 400 nm diameter pore.
Liposomes lipid concentration, size distribution and surface charge (zeta-sizer,
Malvern) were estimated as reported elsewhere31,32, as well as drug encapsulation
efﬁciency after measuring the non-liposomal drug absorption at 284 nm.
In vivo drug treatments. Treatments were initiated 4–14 days post-mouse and 14
days post-human pleural tumour cell injections. Deltarasin (15mg kg 1 in 100ml
PBS), or 100ml PBS were given daily intraperitoneally. Anti-mouse CCL2 or IgG2a
control antibodies were delivered intraperitoneally at 50mg kg 1 in 100 ml PBS
every three days6,7. Deltarasin-encapsulating liposomes were prepared as described
above and elsewhere31,32 and were delivered intrapleurally seven days post-
intrapleural MC38 cells.
Human MPE. MPE cell concentrates from patients with lung adenocarcinoma-
associated MPE from Institution 1 (n¼ 20) were obtained and biobanked
according to standard protocols, were handled similar to mouse MPE samples, and
were subjected to RNA extraction, cDNA synthesis, PCR with human KRAS-
speciﬁc primers (Supplementary Table 1), and direct Sanger sequencing. Some
MPE cells were cultured for one month, tumor cell clones were picked and pooled,
were inoculated into the ﬂank of NOD/SCID mice to test their tumorigenicity, and
were sequenced as above.
Statistics. Sample size was calculated using G*power (http://www.gpower.hhu.de/;47)
assuming errors a¼ 0.05 and b¼ 0.05, and effect size d¼ 1.5. Experiments were done
in a fractionated fashion until statistical signiﬁcance (Po0.05 with ao0.05) was
reached or ruled out (P40.05 with bo0.05). No data were excluded from analyses
and controls and intervention animals were enrolled as necessary per interim power
analyses. Greater numbers of animals were added to follow-up experiments in groups
where outliers increased the dispersion of the data, generating uneven experimental
groups. Animals were allocated to treatments by alternation, and transgenic animals
were enrolled case-control-wise. Data acquisition was blinded on samples previously
coded by a non-blinded investigator. All data were examined for normality by
Kolmogorov–Smirnov test and were found to be normally distributed. Values are
given as frequencies, mean±s.e.m., or mean±s.d., as indicated. Sample size (n) refers
to biological replicates, except from cell line qPCR data, where n refers to technical
replicates. Differences in frequencies were examined by w2 or Fischer’s exact tests, as
appropriate. Differences in means were examined by two-tailed Student’s t-test, or
one-way or two-way ANOVA with Bonferroni post-tests, as appropriate. Survival
proportions were examined by Kaplan–Meier analysis using the log-rank test for
overall and pairwise comparisons. P values are two-tailed, and Po0.05 was considered
signiﬁcant. Analyses and plots were done on Prism v5.0 (GraphPad Software,
La Jolla, CA).
Data availability. The microarray data have been deposited at the Gene Expres-
sion Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) under the accession
codes GSE58190 and GSE85021). The vectors have been deposited at the Addgene
plasmid depository (http://www.addgene.org/Georgios_Stathopoulos/) and plas-
mid ID’s are given in the text. Primary mouse lung adenocarcinoma cells were
deposited at the Laboratory for Molecular Respiratory Carcinogenesis (LMRC)
core cell line facility (http://www.lmrc.upatras.gr/) and are available upon request
(lmrc@upatras.gr). The authors declare that all the other data supporting the
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ﬁndings of this study are available within the article and its Supplementary
Information ﬁles and from the corresponding author upon reasonable request.
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